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The conformational change of a host protein, PrPC, into a disease-
associated isoform, PrPSc, appears to play a critical role in the
pathogenesis of prion diseases such as Creutzfeldt–Jakob disease
and scrapie. However, the fundamental mechanism by which
infectious prions are produced in neurons remains unknown. To
investigate the mechanism of prion formation biochemically, we
conducted a series of experiments using the protein misfolding
cyclic amplification (PMCA) technique with a preparation contain-
ing only native PrPC and copurified lipid molecules. These experi-
ments showed that successful PMCA propagation of PrPSc mole-
cules in a purified system requires accessory polyanion molecules.
In addition, we found that PrPSc molecules could be formed de novo
from these defined components in the absence of preexisting
prions. Inoculation of samples containing either prion-seeded or
spontaneously generated PrPSc molecules into hamsters caused
scrapie, which was transmissible on second passage. These results
show that prions able to infect wild-type hamsters can be formed
from a minimal set of components including native PrPC molecules,
copurified lipid molecules, and a synthetic polyanion.
polyanion  PrP  purified  spontaneous  de novo
A critical event in the pathogenesis of prion disease appears tobe misfolding of the host-encoded prion protein (PrPC) into a
pathogenic isoform (PrPSc). According to the ‘‘protein-only’’ hy-
pothesis, infectious mammalian prions may be comprised exclu-
sively of PrPSc molecules (1). Work using refolded, recombinant
proteins in both mammalian and fungal systems has confirmed the
remarkable concept that pure proteins can harbor infectious prop-
erties (2–4). However, the mechanism by which wild type PrPC
molecules are converted into infectious PrPSc molecules is currently
unknown.
Studies using model systems have also suggested that host-
encoded factors other than PrPC may be required to propagate
prions in vitro and in vivo (5–10). Furthermore, the restricted range
of neuronal and nonneuronal cell types that are susceptible to
infection by prions also suggests the existence of prion propagation
cofactors (11–13). Although no specific cofactors have been iden-
tified to date, several studies have shown that various polyanionic
compounds, such as host-encoded RNA and proteoglycan mole-
cules, appear to stimulate prion-seeded conversion of PrPC into
PrPSc molecules in vitro (10, 14–17).
A powerful approach to identify the requirements for prion
formation is the use of in vitro PrPSc conversion systems, such as the
cell-free conversion assay (18–20) and the protein misfolding cyclic
amplification (PMCA) technique (21–24). Recently, Castilla et al.
(22) serially propagated PrPSc molecules and infectious prions in
vitro by subjecting brain homogenates to PMCA. Building on this
advance, we investigated whether purified PrPC molecules could
function as a substrate for the propagation of PrPSc molecules and
infectious prions in vitro. To perform these studies, it was necessary
to develop a protocol to purify PrPC from native brain tissue
because recombinant PrP produced in Escherichia coli is an inef-
ficient substrate for PMCA reactions, even when reconstituted with
crude brain homogenates (25). During the course of these studies,
we identified conditions under which purified substrates could
propagate infectious prions in vitro and also unexpectedly discov-
ered that infectious prions could be generated spontaneously from
purified, noninfectious components.
Results
Seeded PrPSc Propagation with Purified Substrates. We previously
reported that partially purified hamster PrPC molecules efficiently
convert into a protease-resistant conformation upon incubation
with PrPSc seed and synthetic polyanions in vitro (10). To obtain a
more homogeneous preparation of hamster PrPC substrate for the
current studies, we developed a modified purification protocol
using a combination of detergent solubilization, Protein A agarose,
PrP immunoaffinity, and cation exchange chromatographic steps.
This protocol yielded a preparation containing 30- to 33-kDa
proteins, as determined by SDS/PAGE (Fig. 1, lane 3). We analyzed
the chemical composition of the purified preparation using a variety
of sensitive techniques and detected only hamster PrPC plus
equimolar quantities of 20-carbon fatty acids [described in support-
ing information (SI) Materials and Methods].
To test the ability of purified PrPC to propagate prions in vitro,
we used the serial dilution/propagation protocol described by
Castilla et al. (22) (Fig. 2A). We first tested the ability of several
purified substrate mixtures to facilitate the PMCA propagation of
PrPSc molecules in reactions originally seeded with Sc237 PrP27-30
molecules. The results showed that a substrate mixture containing
both purified PrPC plus synthetic poly(A) RNA molecules success-
fully propagated PrPSc molecules for 16 consecutive rounds of
PMCA (Fig. 2B Bottom), whereas poly(A) RNA or PrPC molecules
alone failed to propagate PrPSc (Fig. 2B Top and Middle). These
results indicate that the propagation of Sc237 PrPSc in vitro requires
both PMCA sonication and an accessory polyanion. No propaga-
tion was obtained without sonication (SI Fig. 5).
To determine whether the propagation of other prion strains
might also require an accessory polyanion, we performed similar
serial PMCA-propagation experiments using 139H PrP27-30 mol-
ecules as the initial seed. Again, PrPC alone failed to propagate
PrPSc, whereas PrPC plus poly(A) RNA successfully propagated
PrPSc during all 16 days tested (Fig. 2C). These results show that in
vitro propagation of 139H PrPSc also depends on the presence of an
accessory polyanion, and therefore the phenomenon of polyanion
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dependence is not limited to the propagation of one specific prion
strain.
We tested other charged polymeric compounds for their ability
to support purified PrPSc propagation and found that only single-
stranded polyanions sufficed for this process (SI Fig. 6). To deter-
mine whether accessory polyanions are also required for the
maintenance of purified PrPSc propagation, we used nuclease-
treated, PMCA-generated PrPSc molecules to seed subsequent
propagation reactions containing either purified PrPC substrate
alone or PrPC plus poly(A) RNA. These experiments confirmed
that polyanions are required to maintain PMCA propagation of
PrPSc molecules (SI Fig. 7).
We next measured the sensitivity of PMCA using purified
substrates. The results of this experiment showed that the minimum
dilution of the PMCA product from a typical PrPSc propagation
experiment required to seed PrPSc formation in the next round is
between 1:5,000 and 1:10,000, and the minimum dilution of the
PMCA product required to seed PrPSc formation after three
successive propagation rounds is 1011 (equivalent to 1 fl of
undiluted PMCA product) (SI Fig. 8). The seven orders of mag-
nitude increase in sensitivity gained by performing three rounds of
PMCA propagation resembles the previously reported increased
sensitivity of multiple-round PMCA reactions using brain homog-
enate substrate (24, 26). We estimate that the concentration of
PrPSc molecules present in a sample of undiluted PMCA product to
be 400 ng/ml as determined by comparison with reference
amounts of recombinant PrP. Using this value, we calculate that the
minimum number of PrPSc molecules required to seed PrPSc
formation in a three-round PMCA propagation experiment is 7
monomers (no. of monomers  reaction volume 100 l  limiting
dilution 1011 estimated PrPSc concentration 400 ng/ml  mo-
nomeric PrP molecular weight 35,000  Avogadro’s number).
Interestingly, this calculated value is close to the measured mini-
mum size of brain-derived infectious scrapie particles (2–6 PrPSc
monomers) (27–29) as well as the minimum number of PrPSc
monomers (equal to 26) required to initiate serial PMCA propa-
gation reactions in crude homogenates (26). It should be noted that
approximately half of the PrPC preparations generated were less
sensitive, i.e., required seed more concentrated than a 1011
dilution of PMCA product to initiate a three-round PMCA prop-
agation experiment; such preparations were not used for subse-
quent experiments.
Spontaneous Formation of PrPSc Molecules. During the studies de-
scribed above, we performed a serial PMCA-propagation experi-
ment using PrPC plus poly(A) RNA substrate that was not originally
seeded with infectious prions. To our surprise, we observed that
PrPSc molecules spontaneously appeared during the ‘‘mock’’ prop-
agation of these unseeded substrates (Fig. 3A). The spontaneously
appearing (de novo) PrPSc molecules migrated on SDS/PAGE with
an apparent molecular mass of 28 kDa after proteinase K
treatment, similar to the apparent molecular mass of brain-derived
Sc237 PrP27-30. Once formed, de novo PrPSc molecules serially
propagated the formation of PrPSc molecules for the remainder of
the experiment.
We next conducted a control experiment to investigate the
possibility that environmental contamination during sonication or
sample processing could have been responsible for the apparently
Fig. 1. Silver stain analysis of purified PrPC substrate. Twelve percent SDS/PAGE
showing (from left to right): crude, detergent-solubilized brain supernatant;
preparation mock-purified from Prnp0/0 mouse brains; preparation purified from
normal hamster brains; and molecular weight markers.
Fig. 2. Seeded PrPSc propagation by using purified substrates. (A) Schematic
diagram of serial dilution and propagation paradigm used in subsequent exper-
iments, adapted from Castilla et al. (22). (B and C) Western blots showing samples
subjected to 16 rounds of PMCA, serial dilution, and propagation as depicted in
A. (B) Samples originally seeded with Sc237 PrP27-30 were propagated in sub-
strate containing either poly(A) RNA alone (top gel), purified PrPC alone (middle
gel), or PrPC plus poly(A) RNA (bottom gel). (C) Samples originally seeded with
139H PrP27-30 were propagated in substrate containing either purified PrPC
alone (top gel), or poly(A) PrPC plus poly(A) RNA (bottom gel). In all gels, a sample
containing PrPC not subjected to proteinase K digestion is shown in the first lane
as a reference for comparison of electrophoretic mobility (PrPC-PK). All other
samples were subjected to limited proteolysis with 50 g/ml proteinase K (PK).
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spontaneous production of PrPSc molecules described above. Spe-
cifically, we purified PrPC substrate and performed an unseeded
propagation experiment entirely in a different laboratory that never
been exposed to prions, using only uncontaminated reagents and
equipment including: commercially purchased frozen brains ob-
tained from hamsters raised in an off-site commercial facility, new
chemical buffers, a new sonicator directly shipped from the man-
ufacturer, a new tube rack, and new sample tubes taken from a
previously unopened container. Daily volume transfers were per-
formed on an open bench within this prion-free environment by
using aerosol barrier pipette tips and disposable gloves. Under these
conditions, we again observed the spontaneous formation of PrPSc,
indicating that PrPSc molecules can form under prion-free condi-
tions (Fig. 3B, experiment designated with # symbol).
We next performed a series of unseeded propagation experi-
ments to characterize the polyanion dependence and kinetics of
spontaneous PrPSc formation. The results show that, whereas
unseeded PMCA reactions containing both PrPC and poly(A) RNA
could produce PrPSc molecules spontaneously, reactions containing
PrPC substrate alone failed to produce de novo PrPSc molecules.
(Fig. 3B). Furthermore, the spontaneous generation of PrPSc in
experiments containing PrPC plus poly(A) RNA appeared to be
stochastic; PrPSc first became detectable during different propaga-
tion rounds in different experiments (Fig. 3 B and C). The stochastic
nature of spontaneous PrPSc formation indicates that this process:
(i) occurs relatively infrequently ( 1 conversion event per 6  1011
input PrPC molecules per PMCA round) and (ii) is unlikely to be
caused by the amplification of preexisting PrPSc molecules.
We also compared the detergent solubility and glycosylation
patterns of de novo PrPSc molecules with brain-derived PrP27-30
and prion-seeded, in vitro-generated PrPSc molecules. The results of
these biochemical studies showed that, like both native and seeded
in vitro-generated PrPSc molecules, de novo PrPSc molecules are
relatively detergent-insoluble (SI Fig. 9) and contain N-linked
glycans (SI Fig. 10).
In Vitro-Generated, Purified PrPSc Molecules Are Infectious. To test
whether in vitro-generated, purified PrPSc molecules are infectious,
we inoculated wild-type hamsters intracerebrally with various sam-
ples derived from our serial PMCA-propagation experiments. The
results of these bioassays show that in vitro-propagated, serially
diluted PrPSc molecules originally seeded with Sc237 or 139H prions
as well as de novo PrPSc molecules formed and propagated without
seeds (including a sample prepared in a prion-free environment by
using new equipment), all caused scrapie in inoculated hamsters
(Table 1). Neuropathological studies revealed typical spongiform
degeneration, astrogliosis, and PrP deposition (Fig. 4), accompa-
nied by the accumulation of PrPSc (SI Fig. 11) in the brains
of hamsters inoculated with either seeded or unseeded PrPSc
molecules.
End-point titration data indicate that, during the course of the
Sc237-seeded propagation experiment, the level of prion infectivity
associated with the final, day-16 PMCA product (5  104 LD50
per ml) was 4-fold lower than the level of infectivity associated
with the input Sc237 PrP27-30 seed (2  105 LD50 per ml) (Table
1). Therefore, during the course of the 16-round, serial dilution
experiment, the level of prion infectivity was relatively maintained,
whereas the initial PrPSc seed was diluted 1015-fold. In contrast,
Sc237-seeded samples propagated in either PrPC or poly(A) RNA
substrate alone contained no prion infectivity detectable by bioas-
say (Table 1). Based on comparisons with known quantities of
recombinant PrP on semiquantitative slot-blot assays, we estimate
that the concentration of PrPSc molecules is 400 ng/ml in the
PMCA product and 40 ng/ml in the PrP27-30 seed. Therefore, we
calculate that there are 1.4  107 in vitro-propagated PrPSc
monomers (based on molecular mass of 35,000 Da) and 4.3  105
PrP27-30 monomers (based on molecular mass of 28,000 Da) per
LD50 unit. It should be noted that there is currently no agreed
definition of ‘‘PrPSc,’’ and therefore our method for measuring
protease-resistant PrPSc molecules should be considered
operational.
The infectious titer of the inoculum containing de novo PrPSc
molecules derived from serial PMCA propagation of PrPC plus
poly(A) RNA substrate mixture for 16 rounds was 5  103 LD50
per ml. In contrast, no prion infectivity could be detected in the
PrPC plus poly(A) RNA substrate mixture not subjected to PMCA
(Table 1). Taken together, these results confirm that prion infec-
tivity was generated de novo during the course of the serial PMCA
propagation experiment, i.e., in the absence of infectious seed
material.
To test whether scrapie caused by in vitro-generated PrPSc
molecules is transmissible, we serially passaged brain homogenates
prepared from animals originally inoculated with samples contain-
ing Sc237-seeded, 139H-seeded, or de novo PrPSc molecules. The
results confirm that scrapie caused by any of the three original
Fig. 3. Formation of PrPSc molecules de novo during serial PMCA propagation
of unseeded purified substrates. (A) Western blot showing unseeded samples
containing PrPC plus poly(A) RNA subjected to 16 rounds of PMCA, serial dilution,
and propagation. A sample containing PrPC not subjected to proteinase K diges-
tion is shown in the first lane as a reference for comparison of electrophoretic
mobility (PrPC-PK).Allother samplesweresubjectedto limitedproteolysiswith50
g/ml proteinase K (PK). (B) Representative slot blot showing the formation of
protease-resistant PrP molecules de novo in multiple propagation experiments.
Unseeded samples were propagated for 15 rounds in either the presence or
absence of poly(A) RNA, as indicated by plus () and minus () symbols, respec-
tively. In experiments designated by asterisks, propagation was not carried be-
yond the 12th round because a preliminary assay performed at that stage already
detected PrPSc in several preceding rounds. The experiment designated by the #
symbol was performed entirely in a prion-free laboratory. (C) Histogram showing
the temporal distribution of the first detectable PrPSc signals during serial prop-
agation of unseeded PrPC plus poly(A) RNA substrate mixtures in 10 separate
propagationexperiments,7ofwhichwerecarriedoutsimultaneously inthesame
sonicator.














inocula could be efficiently transmitted to normal hamsters upon
serial passage (Table 1). The brains of terminally ill animals that
received the serial passage inocula displayed accumulation of PrPSc
(SI Fig. 11A) and severe spongiform degeneration (data not
shown).
Strain Properties of in Vitro-Generated Prions. Originally, we in-
tended to analyze whether inocula derived from Sc237 and 139H
could maintain strain differences upon in vitro propagation with
purified substrates. However, we were unable to perform this
analysis because the incubation time, biochemical, and neuropatho-
logical phenotypes of hamsters inoculated with PrP27-30 molecules
derived from these two strains showed no statistically significant
differences (Table 1; SI Fig. 12A, Fig. 4C, and SI Fig. 11B Upper).
The reason for this apparent strain convergence is currently un-
known but may be related to the digestion of strain-specific,
protease-sensitive sPrPSc conformers during the PrP27-30 purifi-
cation procedure (30, 31) or the removal of the N-terminal octare-
peat region from protease-resistant rPrPSc molecules.
We next sought to compare the strain characteristics of animals
inoculated with brain-derived PrP27-30 molecules to those of
animals inoculated with in vitro-generated PrPSc molecules. Inter-
estingly, animals inoculated with samples containing PrPSc mole-
cules generated by in vitro propagation of Sc237 prions exhibited an
altered relationship between incubation time and infectious titer
compared with animals inoculated with samples containing the
brain-derived Sc237 molecules used as input seed for the propa-
gation experiment (Table 1). At infectious titers between 103 and
105 LD50 units/ml, animals inoculated with Sc237-seeded, in vitro-
generated PrPSc molecules had incubation times 50 days longer
that animals inoculated with brain-derived Sc237 molecules. Ani-
mals inoculated with high concentrations of 139H-seeded in vitro-
generated or de novo PrPSc molecules also displayed long scrapie
incubation times (Table 1). All in vitro-generated PrPSc inocula
displayed shortened incubation times upon second passage
(Table 1).
Clinically, hamsters inoculated with Sc237-seeded, 139H-seeded,
or de novo PrPSc molecules were indistinguishable from each other.
All three groups of animals showed typical signs of scrapie in the
terminal phase, including ataxia, trembling, circling, broad gait, and
inability to maintain or regain upright posture. However, nearly all
of the animals in these three groups also displayed atypical clinical
signs during the early symptomatic phase, namely hyperactivity and
the propensity to climb and hang vertically on cage cover bars. In
contrast, these clinical signs were seldom observed in animals
inoculated with brain-derived PrP27-30. Upon serial passage of
Sc237-seeded, 139H-seeded, and unseeded in vitro-generated PrPSc
inocula, scrapie incubation times were uniformly shortened to 90
days (Table 1), and inoculated animals did not exhibit vertical
climbing activity.
We also examined the neuropathology of hamsters inoculated
with Sc237-seeded, 139H-seeded, and two independently generated
samples of unseeded PrPSc molecules (SI Fig. 12A). The severity of
vacuolation produced by one of the unseeded inocula (prepared
Table 1. Transmission of brain-derived and in vitro-generated prions to normal Syrian hamsters.
Seed (strain) Inoculum Dilution n/n0 IP, days*
Sc237 Input PrP27–30 100 8/8 87 	 3
101 4/4 92 	 2
102 4/4 125 	 44
103 4/4 116 	 29
104 2/4 186 	 94
105 1/3 308
Seeded in vitro propagation with PrPC alone 100 0/5 370
101 0/8 370
Seeded in vitro propagation with RNA alone 100 0/6 370
101 0/7 370
Seeded in vitro propagation with PrPC  RNA 100 8/8 169 	 31
101 8/8 173 	 17
102 6/7 185 	 15
103 3/3 192 	 22
104 0/4 370
105 0/4 370
Serial passage #1 (in vitro propagation with PrPC  RNA) 101 8/8 94 	 12
Serial passage #2 (in vitro propagation with PrPC  RNA) 101 8/8 89 	 14
139H Input PrP27–30 100 8/8 97 	 17
101 8/8 113 	 30
Seeded in vitro propagation with PrPC  RNA 100 8/8 141 	 19
101 6/7 181 	 45
Serial passage #1 (in vitro propagation with PrPC  RNA) 101 8/8 88 	 16
Serial passage #2 (in vitro propagation with PrPC  RNA) 101 8/8 89 	 16
No seed Unseeded PrPC  RNA substrate mixture not subjected to PMCA 101 0/6 360
Repeat unseeded PrPC  RNA substrate mixture not subjected to PMCA
(completely prion-free environment†)
101 0/4 400
Unseeded in vitro propagation with PrPC  RNA 100 7/8 134 	 22
101 7/8 173 	 16




Repeat unseeded in vitro propagation with PrPC  RNA (completely in
prion-free environment†)
101 8/8 168 	 34
Serial passage #1 (in vitro propagation with PrPC  RNA) 101 8/8 85 	 10
Serial passage #2 (in vitro propagation with PrPC  RNA) 101 4/4 87 	 6
*Mean incubation period (IP) of scrapie sick animals 	 SE. All experiments with live animals remaining are ongoing at 370 days.
†These samples were generated in a prion-free laboratory by using new equipment.
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completely in a prion-free environment and indicated by #) was
significantly lower (P  0.05) than the 139H-seeded inoculum in
five of five brain regions, the Sc237-seeded inoculum in four of five
brain regions, and the other unseeded inoculum (indicated by filled
triangles) in one of five brain regions (cerebellum). Furthermore,
the regional pattern of vacuolation produced by this inoculum
differed from the patterns produced by other in vitro-generated
PrPSc inocula in that relatively little vacuolation was observed in the
frontal cortex and hippocampus, compared with other brain regions
(SI Fig. 12A). The severity of vacuolation produced by the other
unseeded inoculum (indicated by filled triangles) more closely
resembled those caused by the seeded inocula (SI Fig. 12A). There
were no statistically significant differences in the PrP deposition
scores measured by immunohistochemistry between any of the
groups inoculated with seeded or unseeded in vitro-generated PrPSc
molecules (SI Fig. 12B). No neuropathological abnormalities were
observed in control animals inoculated with (i) an unseeded PrPC
 poly(A) RNA mixture not subjected to PMCA, (ii) a seeded
sample serially propagated by using PrPC substrate alone, and (iii)
a seeded sample serially propagated by using poly(A) RNA alone.
(SI Fig. 13 and Fig. 4 B and C). These negative diagnostic results
confirm that the PrPC and poly(A) RNA substrates are not them-
selves contaminated with prions or any other neurotropic infectious
agents.
Biochemically, the guanidine denaturation profiles of protease-
resistant PrPSc molecules in the brains of hamsters inoculated with
seeded and unseeded in vitro-generated PrPSc molecules as well as
brain derived PrP27-30 molecules were nearly indistinguishable (SI
Fig. 11B).
Discussion
Accessory Polyanions Facilitate Prion Formation in Vitro. Our obser-
vation that efficient PMCA propagation of infectious prions in vitro
requires an accessory polyanion raises the possibility that endoge-
nous polyanionic cofactors may participate in prion propagation in
vivo, either as catalysts or as scaffolds complexed to PrPSc mole-
cules. Further studies are required to distinguish between these
possibilities and to identify the specific endogenous polyanions that
facilitate prion propagation in vivo. Several classes of negatively
charged macromolecules could potentially serve as cofactors for
prion propagation, including: nucleic acids (17, 32–38), glycosami-
noglycans (14–16), phospholipid-rich membranes (39–42), and
chaperone proteins (43). Interestingly, it has been proposed that
polyanions could play a broad role in protein folding and misfold-
ing, and the ability of polyanions to facilitate prion conversion may
represent a specific example of that general concept (44). It has also
been proposed that binding of specific RNA molecules to PrPSc
could determine strain properties (45). We observed that two
independently generated samples of de novo PrPSc molecules
prepared by using purified PrPC plus synthetic poly(A) RNA
substrates produced moderately different regional vacuolation pro-
files in hamsters. This result indicates that, although polyanions
might constrain the folding potential of PrP molecules, purified
prions formed spontaneously in the presence of poly(A) RNA can
display at least some degree of conformational heterogeneity. More
work is required to determine whether polyanions can influence
prion strain properties.
It has been previously reported that refolding pure, recombinant
PrP into amyloid fibers in the absence of polyanions could produce
synthetic mammalian prions (2). Several possible explanations
could account for the discrepancy between the results of that study
and our demonstration that polyanions are necessary for prion
formation in vitro. (i) Recombinant PrP amyloid fibrils may interact
with endogenous polyanions in situ after inoculation. An observa-
tion consistent with this possible explanation is that synthetic prions
formed from recombinant PrP molecules display unique biochem-
ical and neuropathological strain properties upon initial inoculation
into transgenic mice expressing truncated PrPC molecules but
subsequently cause typical scrapie (resembling infection with the
murine RML prion strain) upon serial passage into wild-type mice
(2, 46). (ii) Polyanions may not be absolutely required to form an
infectious prion, but may increase the efficiency of prion conver-
sion. High concentrations of recombinant PrP were used to produce
disease with very long incubation times in Tg mice overexpressing
PrP, and therefore it is possible that the specific infectivity of PrP
amyloid formed without polyanions may be substantially lower than
the specific infectivity of PrPSc molecules formed in the presence of
polyanions. The in vitro-prions generated in our experiments also
produced longer initial incubation times than brain-derived prions;
one possible explanation for this effect is that poly(A) RNA may be
an imperfect cofactor for forming hamster prions. (iii) Differences
in specific experimental conditions (e.g., PrP preparation method,
buffer composition, reaction pH, or the presence of denaturants)
could account for the apparent difference in polyanion requirement
between the two systems. More work is required to determine the
reason that polyanions are required to produce infections prions in
PMCA experiments but not in the in vitro folding experiments
reported by Legname et al. (2).
Spontaneous Generation of Infectious Prions: a Model of Sporadic
Prion Disease. The mechanism by which PrPSc molecules and
infectious prions originate in sporadic Creutzfeldt–Jakob disease
(sCJD) is not known, and no experimental model of this disease has
previously been described. PrPSc molecules invariably accumulate
in the brains of patients with sCJD, and the disease can be
experimentally transmitted to normal primates (47). Several hy-
potheses have been proposed to explain the etiology of sCJD,
including: stochastic formation of PrPSc molecules (48), somatic
mutation of PrP sequence in individual brain cells (49), and
age-dependent decline in PrPSc clearance mechanisms (50). Our
results suggest that interactions between PrPC molecules and en-
dogenous polyanions may contribute to the relatively infrequent
process of prion formation in patients with sCJD.
Several lines of evidence indicate that prions form spontaneously
Fig. 4. Representative histological fields of the CA2 hippocampus region in
control animals and animals inoculated with in vitro-generated PrPSc molecules.
Rows from top to bottom: (top row) uninoculated, normal 190 day old hamster;
(second row) terminally ill hamster inoculated with Sc237-seeded, serially prop-
agated PrPSc molecules; (third row) terminally ill hamster inoculated with 139H-
seeded, serially propagated PrPSc molecules; (bottom row) terminally ill hamster
inoculated with spontaneously generated, serially propagated PrPSc molecules.
Hematoxylin and eosin (H&E) staining, as well as glial fibrillary acidic protein
(GFAP) and PrP immunohistochemical staining results are shown for each group.
(Scale bar, 100 m.)














at low frequency in unseeded experiments, rather than by ampli-
fication of preexisting prions. (i) Most importantly, de novo PrPSc
molecules were generated in a completely prion-free laboratory, by
using only new or prion-free equipment and source materials. (ii)
The appearance of de novo PrPSc molecules appears to be stochas-
tic, whereas one might expect that contaminating PrPSc molecules
would be amplified in a more stereotypic manner during the course
serial propagation experiments. (iii) De novo PrPSc molecules
generated in a prion-free environment were infectious, whereas
various negative control samples were not. Interestingly, this sample
produced a unique regional profile characterized by relatively mild
vacuolation in the frontal cortex and hippocampus, compared with
other samples containing either PrP27-30 or in vitro-generated
PrPSc molecules.
Although less likely, it is also possible that normal hamsters have
low levels of endogenous PrPSc molecules in their brains. Previous
experiments have shown that PrPSc molecules can persist chroni-
cally in animals without causing disease (51–53). In this scenario,
the rate of endogenous PrPSc production in normal animals
might be balanced by a putative clearance mechanism, prevent-
ing accumulation.
Limiting the Possible Composition of Infectious Prions. The results
presented in this article indicate that a purified PrPC preparation
plus an accessory polyanion can serve as substrates for in vitro prion
propagation. Therefore, we can logically limit the possible compo-
sition of the scrapie agent to, at most, these defined components.
More work is required to determine whether the accessory polya-
nion component functions as an unbound catalyst or is physically
complexed to PrPSc within infectious prions. We detected approx-
imately equimolar levels of several unsaturated 20-carbon fatty
acids, including several isomers of arachidonic acid, in our purified
PrPC preparations. The only fatty acid previously identified as a
component of the PrP GPI anchor is stearic acid, a saturated
18-carbon compound (54), and therefore it is likely that the
copurified fatty acids are not covalently bound to PrPC. Phospho-
lipids have been shown to influence the folding of recombinant PrP
molecules (40–42), and it will be interesting in future studies to
determine whether lipids might also regulate the formation of PrPSc
molecules in PMCA reactions.
Materials and Methods
PrPC and PrP27-30 molecules were purified by using modified
versions of previously published protocols (55). PMCA and serial
dilution/propagation experiments were performed as described
(22) by using purified substrates instead of brain homogenates.
Standard bioassay and neuropathology techniques were used to
measure prion infectivity and strain properties (56). PrPSc stability
was assayed as described (46). Detailed descriptions for each of
these techniques, statistical methods, and chemical analyses are
provided in SI Materials and Methods.
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